The new site at www.horizondiscovery.com features enhanced content, including customer-focused information demonstrating the value Horizon can add across the drug discovery & development continuum, and in diagnostics. The site also includes a full online ordering system for its X-MAN™ range of genetically-defined disease model cell lines and related products.
Horizon combines a long scientific heritage in translational research with a world-leading gene editing platform, rAAV GENESIS™, based upon homologous recombination. The Company supplies genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development.
Horizon aspires to provide science-driven research solutions that lead to advancement in the understanding of the genetic basis of disease and the delivery of better healthcare outcomes for patients.
About Horizon Discovery
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. Using GENESISTM, the Company’s proprietary rAAV gene-editing technology, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell-line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Horizon has applied GENESIS to create over 500 X-MAN™ cell lines, the world’s first source of genetically-defined and patient-relevant human cell lines, accurately modeling the disease-causing mutations found in cancer patients. These ‘patients-in-a-test-tube’ are being used by academic and industry leaders to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, leading to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments. This enables the design of shorter, more focused, and less expensive clinical trials, ultimately providing the tools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutations that define their disease.
In addition to the X-MAN cell lines, Horizon provides GENESIS and X-MAN™ derived products and services, with industrial application in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomic-based clinical research platforms.
GENESIS and X-MAN are registered trademarks of Horizon Discovery Limited.
*******
Contact:
Katie Odgaard
Zyme Communications Ltd
Tel: +44 (0)7787 502 947
E-mail: katie.odgaard@zymecommunications.com
_________________________________________________